We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-16.47%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$41.5M
AUM Growth
-$311M
Cap. Flow
-$295M
Cap. Flow %
-711.77%
Top 10 Hldgs %
86.71%
Holding
72
New
5
Increased
–
Reduced
17
Closed
48

Top Buys

Rank Stock Value
1
LGMK
LogicMark
LGMK
+$3.72M
2
SKYA
SkyAI Inc
SKYA
+$3.02M
3
INBS icon
Intelligent Bio Solutions
INBS
+$278K
4
SBFM
Sunshine Biopharma
SBFM
+$127K

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$23.9M
2
VERA icon
Vera Therapeutics
VERA
+$18.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$15.4M
4
ESTA icon
Establishment Labs
ESTA
+$14.1M
5
EW icon
Edwards Lifesciences
EW
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.55%
2 Technology 0.27%
3 Consumer Staples 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
26
AnaptysBio
ANAB
$1.67B
– –
-18,326
Closed -$243K
ANAB icon
27
PUT
AnaptysBio
ANAB
$1.67B
– –
-206,200
Closed -$2.73M
APLT
28
PUT
DELISTED
Applied Therapeutics
APLT
– –
-56,100
Closed -$48K
ARGX icon
29
argenx
ARGX
$54.5B
– –
-10,000
Closed -$6.15M
ARWR icon
30
Arrowhead Research
ARWR
$12.3B
– –
-230,257
Closed -$4.33M
ATEC icon
31
Alphatec Holdings
ATEC
$1.41B
– –
-264,562
Closed -$2.43M
BCYC
32
Bicycle Therapeutics
BCYC
$292M
– –
-40,352
Closed -$565K
BHVN icon
33
Biohaven
BHVN
$2.23B
– –
-250,000
Closed -$9.34M
CAPR icon
34
Capricor Therapeutics
CAPR
$242M
– –
-714,000
Closed -$9.85M
CATX icon
35
Perspective Therapeutics
CATX
$342M
– –
-92,224
Closed -$294K
CLRB icon
36
Cellectar Biosciences
CLRB
$20.5M
– –
-7,167
Closed -$64.3K
CMPS
37
Compass Pathways
CMPS
$1.82B
– –
-1,424,400
Closed -$5.38M
CPRX
38
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-255,000
Closed -$5.32M
CRBP icon
39
Corbus Pharmaceuticals
CRBP
$185M
– –
-385,000
Closed -$4.54M
CTMX icon
40
CytomX Therapeutics
CTMX
$740M
– –
-467,491
Closed -$482K
ESTA icon
41
CALL
Establishment Labs
ESTA
$2.3B
– –
-300,000
Closed -$13.8M
ESTA icon
42
Establishment Labs
ESTA
$2.3B
– –
-305,000
Closed -$14.1M
EW icon
43
Edwards Lifesciences
EW
$51.5B
– –
-165,000
Closed -$12.2M
EXAS
44
DELISTED
Exact Sciences
EXAS
– –
-100,000
Closed -$5.62M
FULC icon
45
Fulcrum Therapeutics
FULC
$292M
– –
-111,812
Closed -$526K
GKOS icon
46
Glaukos
GKOS
$10.5B
– –
-40,000
Closed -$6M
IBRX icon
47
ImmunityBio
IBRX
$7.96B
– –
-1,060,000
Closed -$2.71M
INSM icon
48
Insmed
INSM
$28.2B
– –
-132,000
Closed -$9.11M
KROS icon
49
Keros Therapeutics
KROS
$216M
– –
-175,000
Closed -$2.77M
LRMR icon
50
CALL
Larimar Therapeutics
LRMR
$430M
– –
-396,000
Closed -$1.53M
1
2
3

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CF
Crosspoint Financial Tustin, California $39.8M AUM 14.13% 1-Year Est. Return

Altium Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Altium Capital Management held 72 positions worth $41.5M, down 88% from $353M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Altium Capital Management withdrew a net $295M in Q1 2025, closing 48 positions and reducing 17 holdings. Its most notable exit was ADMA Biologics, an estimated $23.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 91% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Altium Capital Management opened a new position in LogicMark worth $107K.

  • Altium Capital Management's largest Q1 2025 buy was LogicMark: 5,395,308 shares worth $107K.
  • Altium Capital Management's biggest Q1 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $8.65M.
  • Altium Capital Management fully exited ADMA Biologics in Q1 2025, selling an estimated $23.9M.
  • Altium Capital Management's ten largest holdings make up 87% of its $41.5M portfolio in Q1 2025.
  • Altium Capital Management opened 5 new positions and closed 48 in Q1 2025.
  • Altium Capital Management's portfolio value fell 88% quarter-over-quarter to $41.5M.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.